Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Apr 16, 2025
Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types
Continued progress of lead program, AKTX-101, for the treatment of solid tumors
Read more at globenewswire.com
